1
|
Campanella A, Capasso A, Heltai S, Taccetti C, Albi E, Herishanu Y, Haggenburg S, Chatzikonstantinou T, Doubek M, Kättström M, Giannopoulos K, Simkovic M, Moreno C, Massaia M, Bumbea H, Alshemmari S, Ranghetti P, Perotta E, Martini F, Sant'Antonio E, Colia M, Combi C, Levi S, Kater AP, Hazenberg M, Nijhof IS, Hofsink Q, Demosthenous C, Kotaskova J, Zaleska J, Vrbacky F, Raya AM, Bisogno D, Tripoli IE, Popov VM, Roman V, Stavroyianni N, Karypidou M, Scarano E, Locatelli M, Frenquelli M, Scarfò L, Stamatopoulos K, Ghia P. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL. Am J Hematol 2024; 99:745-750. [PMID: 38264829 DOI: 10.1002/ajh.27218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Revised: 12/21/2023] [Accepted: 01/01/2024] [Indexed: 01/25/2024]
Abstract
Profound immune dysregulation and impaired response to the SARS-CoV-2 vaccine put patients with chronic lymphocytic leukemia (CLL) at risk of severe COVID-19. We compared humoral memory and T-cell responses after booster dose vaccination or breakthrough infection. (Green) Quantitative determination of anti-Spike specific antibodies. Booster doses increased seroconversion rate and antibody titers in all patient categories, ultimately generating humoral responses similar to those observed in the postinfection cohort. In detail, humoral response with overscale median antibody titers arose in >80% of patients in watch and wait, off-therapy in remission, or under treatment with venetoclax single-agent. Anti-CD20 antibodies and active treatment with BTK inhibitors (BTKi) represent limiting factors of humoral response, still memory mounted in ~40% of cases following booster doses or infection. (Blue) Evaluation of SARS-CoV-2-specific T-cell responses. Number of T-cell functional activation markers documented in each patient. The vast majority of patients, including those seronegative, developed T-cell responses, qualitatively similar between treatment groups or between vaccination alone and infection cases. These data highlight the efficacy of booster doses in eliciting T-cell immunity independently of treatment status and support the use of additional vaccination boosters to stimulate humoral immunity in patients on active CLL-directed treatments.
Collapse
Affiliation(s)
- A Campanella
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| | - A Capasso
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| | - S Heltai
- IRCCS San Raffaele Hospital, Milan, Italy
| | - C Taccetti
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| | - E Albi
- IRCCS San Raffaele Hospital, Milan, Italy
| | - Y Herishanu
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
- Tel Aviv University, Tel-Aviv, Israel
| | | | | | - M Doubek
- University Hospital Brno, Brno, Czech Republic
| | - M Kättström
- Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
| | | | - M Simkovic
- 4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic
| | - C Moreno
- Hospital de la Santa Creu I Sant Pau, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
| | - M Massaia
- AO S.Croce e Carle, Cuneo, Italy
- Turin University, Turin, Italy
| | - H Bumbea
- University Emergency Hospital, Bucharest, Romania
- University of Medicine and Pharmacy, Carol Davila, Bucharest, Romania
| | - S Alshemmari
- Department of Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait
| | | | - E Perotta
- IRCCS San Raffaele Hospital, Milan, Italy
| | - F Martini
- IRCCS San Raffaele Hospital, Milan, Italy
| | | | - M Colia
- IRCCS San Raffaele Hospital, Milan, Italy
| | - C Combi
- IRCCS San Raffaele Hospital, Milan, Italy
| | - S Levi
- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - A P Kater
- Amsterdam UMC, Amsterdam, The Netherlands
| | | | - I S Nijhof
- Amsterdam UMC, Amsterdam, The Netherlands
- St Antonius Hospital, Nieuwegein, The Netherlands
| | - Q Hofsink
- Amsterdam UMC, Amsterdam, The Netherlands
| | - C Demosthenous
- Centre for Research and Technology Hellas, Thessaloniki, Greece
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - J Kotaskova
- University Hospital Brno, Brno, Czech Republic
- Central European Institute of Technology, Masaryk University, Brno, Czech Republic
| | - J Zaleska
- Medical University of Lublin, Lublin, Poland
| | - F Vrbacky
- 4th Department of Internal Medicine - Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Kralove, Czech Republic
| | - A Mora Raya
- Hospital de la Santa Creu I Sant Pau, Josep Carreras Leukaemia Research Institute, Barcelona, Spain
| | | | - I E Tripoli
- AO S.Croce e Carle, Cuneo, Italy
- Turin University, Turin, Italy
| | - V M Popov
- Colentina Clinical Hospital, Bucharest, Romania
| | - V Roman
- Center of Immunology Department, Stefan S. Nicolau Institute of Virology, Bucharest, Romania
| | - N Stavroyianni
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - M Karypidou
- Centre for Research and Technology Hellas, Thessaloniki, Greece
| | - E Scarano
- IRCCS San Raffaele Hospital, Milan, Italy
| | - M Locatelli
- Laboratory Medicine Service, IRCCS San Raffaele Hospital, Milano, Italy
| | | | - L Scarfò
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| | - K Stamatopoulos
- Centre for Research and Technology Hellas, Thessaloniki, Greece
| | - P Ghia
- Vita Salute San Raffaele University, Milan, Italy
- IRCCS San Raffaele Hospital, Milan, Italy
| |
Collapse
|
2
|
Vrbacky F, Fatorova I, Blazek M, Smahel P, Zak P. Intensive Care Infection Score (ICIS) is elevated in patients with moderate and severe COVID-19 in the early stages of disease. J Infect Public Health 2022; 15:533-538. [PMID: 35461075 PMCID: PMC8972975 DOI: 10.1016/j.jiph.2022.03.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Revised: 03/18/2022] [Accepted: 03/28/2022] [Indexed: 01/08/2023] Open
Abstract
Background Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus is still a very dangerous and life-threatening disease with an extremely heterogeneous course. Older patients and those with comorbidities are at increased risk of death from the disease but young patients can develop potentially lethal complications too. For those reasons, numerous recent studies focus on the analysis of markers associated with early assessment of COVID-19 prognosis. Previous publications provided evidence for the Intensive Care Infection Score (ICIS) as an easy to use tool to assess the risk for bacterial infection in ICU patients based on a combination of haematologic parameters. This study evaluated the performance of ICIS as a prognostic marker of stages of disease in COVID-19 patients. Methods A total of 205 COVID-19 patients admitted to the University Hospital Hradec Kralove, Czech Republic, with symptoms of respiratory tract infection and a positive RT-PCR test for SARS-CoV-2 virus were enrolled in this study. Forty-nine patients developed mild COVID-19 symptoms (no oxygen therapy needed), 156 patients developed moderate or severe symptoms (supplemental oxygen therapy or death). Results ICIS predicted the mild or moderate/severe course with the highest AUC (0.773). The cut-off value (ICIS = 3.5) was selected as the value with the highest Youden index (0.423). The cut-off value could predict a mild or moderate/severe course of the disease with the highest specificity (77.6%) and positive predictive value (90.2%) of all markers used in this study. Sensitivity was 64.7%. Conclusion ICIS is a reliable, cheap, fast and simply interpretable score for the early identification of moderate/severe course of COVID-19 in an early stage of the disease. ICIS> 3 predicts a severe course of the disease with high specificity and positive predictive value.
Collapse
Affiliation(s)
- Filip Vrbacky
- 4th Department of Internal Medicine - Haematology, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, Hradec Kralove, Czech Republic.
| | - Ilona Fatorova
- 4th Department of Internal Medicine - Haematology, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, Hradec Kralove, Czech Republic
| | - Martin Blazek
- Pulmonary Department, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, Hradec Kralove, Czech Republic
| | - Petr Smahel
- Department of Infectious Diseases, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, Hradec Kralove, Czech Republic
| | - Pavel Zak
- 4th Department of Internal Medicine - Haematology, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Sokolska 581, Hradec Kralove, Czech Republic
| |
Collapse
|
3
|
Belohlavkova P, Vrbacky F, Smolej L, Radocha J, Lanska M, Visek B, Kupsa T, Zavrelova A, Zak P. Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome. Leuk Res Rep 2021; 16:100274. [PMID: 34760617 PMCID: PMC8566995 DOI: 10.1016/j.lrr.2021.100274] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Revised: 09/19/2021] [Accepted: 10/16/2021] [Indexed: 11/26/2022] Open
Abstract
In the present study, we retrospectively analysed the results of HSCT in 47 consecutive patients with MDS diagnosed at our department between 2002 and 2019, with a focus on possible predictive factors influencing overall survival (OS), the development of relapse, infections, and the occurrence of graft versus host disease (GvHD). In a univariate analysis, the pre-transplantation value of blasts in the marrow < 5% (p = 0.006), the revised International Prognostic Scoring System (IPSS-R) (p = 0.041), and karyotype (p = 0.009) were predictive of OS. Neither the elevation of serum ferritin (> 1000 ug/ml) nor increased C-reactive protein (CRP) (> 5 mg/l) was associated with shorter OS. In contrast, elevated serum lactate dehydrogenase (LDH) (> 213 U/l) was associated with shorter OS (p = 0.04).
Collapse
Affiliation(s)
- P Belohlavkova
- 4th Department of Internal Medicine - Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
| | - F Vrbacky
- 4th Department of Internal Medicine - Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
| | - L Smolej
- 4th Department of Internal Medicine - Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
| | - J Radocha
- 4th Department of Internal Medicine - Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
| | - M Lanska
- 4th Department of Internal Medicine - Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
| | - B Visek
- 4th Department of Internal Medicine - Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
| | - T Kupsa
- 4th Department of Internal Medicine - Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
| | - A Zavrelova
- 4th Department of Internal Medicine - Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
| | - P Zak
- 4th Department of Internal Medicine - Haematology, University Hospital and Charles University, Hradec Kralove, Czech Republic
| |
Collapse
|
4
|
Baranova I, Kovarikova H, Laco J, Sedlakova I, Vrbacky F, Kovarik D, Hejna P, Palicka V, Chmelarova M. Identification of a four-gene methylation biomarker panel in high-grade serous ovarian carcinoma. Clin Chem Lab Med 2021; 58:1332-1340. [PMID: 32145055 DOI: 10.1515/cclm-2019-1319] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Accepted: 02/04/2020] [Indexed: 12/31/2022]
Abstract
Background The lack of effective biomarkers for the screening and early detection of ovarian cancer (OC) is one of the most pressing problems in oncogynecology. Because epigenetic alterations occur early in the cancer development, they provide great potential to serve as such biomarkers. In our study, we investigated a potential of a four-gene methylation panel (including CDH13, HNF1B, PCDH17 and GATA4 genes) for the early detection of high-grade serous ovarian carcinoma (HGSOC). Methods For methylation detection we used methylation sensitive high-resolution melting analysis and real-time methylation specific analysis. We also investigated the relation between gene hypermethylation and gene relative expression using the 2-ΔΔCt method. Results The sensitivity of the examined panel reached 88.5%. We were able to detect methylation in 85.7% (12/14) of early stage tumors and in 89.4% (42/47) of late stage tumors. The total efficiency of the panel was 94.4% and negative predictive value reached 90.0%. The specificity and positive predictive value achieved 100% rates. Our results showed lower gene expression in the tumor samples in comparison to control samples. The more pronounced downregulation was measured in the group of samples with detected methylation. Conclusions In our study we designed the four-gene panel for HGSOC detection in ovarian tissue with 100% specificity and sensitivity of 88.5%. The next challenge is translation of the findings to the less invasive source for biomarker examination, such as plasma. Our results indicate that combination of examined genes deserve consideration for further testing in clinical molecular diagnosis of HGSOC.
Collapse
Affiliation(s)
- Ivana Baranova
- Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Helena Kovarikova
- Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Jan Laco
- The Fingerland Department of Pathology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Iva Sedlakova
- Department of Obstetrics and Gynecology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Filip Vrbacky
- The 4th Department of Internal Medicine - Hematology, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Dalibor Kovarik
- Department of Forensic Medicine, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Petr Hejna
- Department of Forensic Medicine, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Vladimir Palicka
- Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Marcela Chmelarova
- Institute of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| |
Collapse
|
5
|
Kukla R, Bolehovska R, Radocha J, Pliskova L, Zak P, Vrbacky F, Nekvindova J, Zemlickova H. Improved laboratory diagnostics of Streptococcus pneumoniae in respiratory tract samples through qPCR. New Microbiol 2020; 43:70-77. [PMID: 32310299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Accepted: 06/08/2020] [Indexed: 06/11/2023]
Abstract
The aim of this study was to test the detection performance of the cpsA, lytA and ply genes through qPCR in the identification of Streptococcus pneumoniae in respiratory tract samples. Specificity was tested on a panel of 128 streptococci and other bacteria DNA samples. The qPCR assay was tested on a total of 51 respiratory tract samples from patients with community-acquired pneumonia (CAP). The specificity of the cpsA, lytA and ply genes was 100%, 100%, and 86%, respectively. The quantitative assessment, based on lytA, determined a cutoff value of ~2x104, 4x102 and 4x102 DNA copies per 1 mL of valid sputum, tracheal aspirate and bronchial aspirate samples, respectively. The results from the present study suggest that qPCR detection of all three genes would be optimal in the accurate detection of Streptococcus pneumoniae.
Collapse
Affiliation(s)
- Rudolf Kukla
- Department of Clinical Microbiology, University Hospital Hradec Kralove, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic
| | - Radka Bolehovska
- Department of Clinical Microbiology, University Hospital Hradec Kralove, Czech Republic
| | - Jakub Radocha
- 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic
| | - Lenka Pliskova
- Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Czech Republic
| | - Pavel Zak
- 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic
| | - Filip Vrbacky
- 4th Department of Internal Medicine - Hematology, Faculty Hospital, Charles University, Hradec Kralove, Czech Republic
| | - Jana Nekvindova
- Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Czech Republic
| | - Helena Zemlickova
- Department of Clinical Microbiology, University Hospital Hradec Kralove, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic
- National Reference Laboratory for Antibiotics, National Institute of Public Health, Prague, Czech Republic
| |
Collapse
|
6
|
Belohlavkova P, Steinerova K, Karas M, Skoumalova I, Rohon P, Indrak K, Voglova J, Vrbacky F, Cmunt E, Necasova T, Kristkova Z, Trneny M, Zak P, Papajik T, Faber E. First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter. Leuk Res 2019; 81:67-74. [DOI: 10.1016/j.leukres.2019.04.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2019] [Revised: 04/18/2019] [Accepted: 04/23/2019] [Indexed: 10/26/2022]
|
7
|
Petrova L, Vrbacky F, Lanska M, Zavrelova A, Zak P, Hrochova K. Corrigendum to ‘IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?’ Clinical Biochemistry 61 (2018) 34–39. Clin Biochem 2019; 63:161. [DOI: 10.1016/j.clinbiochem.2018.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Belohlavkova P, Vrbacky F, Voglova J, Racil Z, Zackova D, Hrochova K, Malakova J, Mayer J, Zak P. The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients. Arch Med Sci 2018; 14:1416-1423. [PMID: 30393497 PMCID: PMC6209720 DOI: 10.5114/aoms.2018.73538] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 11/16/2017] [Indexed: 12/15/2022] Open
Abstract
INTRODUCTION Imatinib mesylate is the drug of choice for patients with chronic myeloid leukemia (CML). Imatinib pharmacokinetics is affected by a number of transport proteins and enzymes. MATERIAL AND METHODS In the present study we evaluated the association of eight polymorphisms in the seven genes CYP3A5*3 (rs776746), CYP3A4*1 (rs2740574), CYP2C9*3 (rs1057910), SLC22A1 (rs683369), ABCB1 (rs1045642, rs1128503), ABCG2 (rs2231142) and ABCC2 (rs717620) with imatinib plasma level and achieving an optimal clinical response in 112 CML patients (53 men and 59 women). RESULTS No association was found between the examined polymorphisms in rs776746, rs2740574, rs1057910, rs683369, rs1045642, rs1128503, rs2231142, rs717620 and the achieved imatinib plasma level. The influence of rs776746 (CYP3A5*3) on the achievement of a complete cytogenetic response (CCyR) at 6 months was borderline non-significant (p = 0.06). Furthermore, no association was demonstrated between rs776746 polymorphisms and the achievement of a major molecular response (MMR) at 12 or 18 months. Polymorphisms rs776746, rs2740574, rs1057910, rs683369, rs1045642, rs1128503, rs2231142, rs717620 showed no impact on the optimal therapeutic response. CONCLUSIONS Despite the results of some other studies, no other polymorphism we analyzed was associated with imatinib plasma level or clinical response. The treatment outcomes cannot be predicted using the candidate gene approach and treatment decisions cannot be made according to the polymorphisms investigated in this study.
Collapse
Affiliation(s)
- Petra Belohlavkova
- 4 Department of Internal Medicine – Hematology, Charles University Hospital, Hradec Kralove, Czech Republic
| | - Filip Vrbacky
- 4 Department of Internal Medicine and Hematology, Charles University, Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Jaroslava Voglova
- 4 Department of Internal Medicine and Hematology, Charles University, Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Zdenek Racil
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - Daniela Zackova
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - Katerina Hrochova
- Department of Clinical Biochemistry, Charles University, Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Jana Malakova
- Department of Clinical Biochemistry, Charles University, Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Jiri Mayer
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - Pavel Zak
- 4 Department of Internal Medicine and Hematology, Charles University, Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| |
Collapse
|
9
|
Petrova L, Vrbacky F, Lanska M, Zavrelova A, Zak P, Hrochova K. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring? Clin Biochem 2018; 61:34-39. [PMID: 30176240 DOI: 10.1016/j.clinbiochem.2018.08.012] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 08/30/2018] [Accepted: 08/30/2018] [Indexed: 12/21/2022]
Abstract
OBJECTIVES Molecular screening plays a major role in prognostic categorization and subsequent definition of treatment strategies for acute myeloid leukemia. The possibility of using IDH1/2 mutations as a marker for the monitoring of minimal residual disease (MRD) is still under investigation and remains unclear. METHODS In this retrospective study, we evaluated 90 patients with de novo AML using Sanger sequencing (exon 4, IDH1 and IDH2). For subsequent MRD monitoring were used both methods, massive parallel sequencing and droplet digital PCR (ddPCR). RESULTS We identified 22 patients (24%) who harboured mutations in IDH1 or IDH2 genes. Fourteen (64%) of them had other commonly used MRD markers (insertion in NPM1 and partial tandem duplication of MLL, MLL-PTD). Eight of the 22 patients had IDH1 mutations, 13 had IDH2 mutations and 1 had both IDH1 and IDH2 mutations. In our cohort, this IDH1/2 marker responded to the treatment in all of the patients and reflected the onset of the relapse very well. NPM1 mutation based MRD monitoring was more sensitive and predicted relapse earlier but IDH1/2 based monitoring was more sensitive than a method based on MLL-PTD. Both massive parallel sequencing and ddPCR were competent to monitor MRD using IDH1/2. Nevertheless, ddPCR was able to achieve a higher sensitivity in some cases and moreover this method can analyse a single sample without significant price increases. CONCLUSION Given these data, we conclude that IDH1/2 mutations can be used as a reliable and cost-effective marker for MRD monitoring.
Collapse
MESH Headings
- Adult
- Aged
- Amino Acid Substitution
- Cohort Studies
- Czech Republic
- DNA Mutational Analysis
- Exons
- Female
- Follow-Up Studies
- Genetic Association Studies
- Genetic Predisposition to Disease
- Hospitals, University
- Humans
- Isocitrate Dehydrogenase/chemistry
- Isocitrate Dehydrogenase/genetics
- Isocitrate Dehydrogenase/metabolism
- Leukemia, Myeloid, Acute/diagnosis
- Leukemia, Myeloid, Acute/enzymology
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/therapy
- Male
- Middle Aged
- Mutation
- Neoplasm, Residual
- Nucleophosmin
- Prognosis
- Remission Induction
- Retrospective Studies
Collapse
Affiliation(s)
- Lucie Petrova
- Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
| | - Filip Vrbacky
- 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Miriam Lanska
- 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Alzbeta Zavrelova
- 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Pavel Zak
- 4th Department of Internal Medicine - Haematology, University Hospital Hradec Králové and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Katerina Hrochova
- Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czech Republic
| |
Collapse
|
10
|
Jaruskova M, Curik N, Hercog R, Polivkova V, Motlova E, Benes V, Klamova H, Pecherkova P, Belohlavkova P, Vrbacky F, Machova Polakova K. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment. J Exp Clin Cancer Res 2017; 36:55. [PMID: 28420426 PMCID: PMC5395939 DOI: 10.1186/s13046-017-0523-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 03/31/2017] [Indexed: 01/06/2023]
Abstract
Background Through high-throughput next-generation sequencing of promoters of solute carrier and ATP-binding cassette genes, which encode drug transporters, we aimed to identify SNPs associated with the response to imatinib administered for first-line treatment of patients with chronic myeloid leukemia. Methods In silico analysis using publicly available databases was done to select the SLC and ABC genes and their promoters for the next-generation sequencing. SNPs associated with the imatinib response were identified using Fisher’s exact probability tests and subjected to the linkage disequilibrium analyses with regulatory loci of concerned genes. We analyzed cumulative achievement of major molecular response and probability of event free survival in relation to identified SNP genotypes in 129 CML patients and performed multivariate analysis for determination of genotypes as independent predictors of outcome. Gene expression analysis of eight cell lines naturally carrying different genotypes was performed to outline an impact of genotypes on the gene expression. Results We observed significant differences in the frequencies of the rs460089-GC and rs460089-GG (SLC22A4) genotypes among rs2631365-TC (SLC22A5) genotype carriers that were associated with optimal and non-optimal responses, respectively. Loci rs460089 and rs2631365 were in highly significant linkage disequilibrium with 12 regulatory loci in introns of SLC22A4 and SLC22A5 encoding imatinib transporters. Genotype association analysis with the response to imatinib indicated that rs460089-GC carriers had a significantly higher probability of achieving a stable major molecular response (BCR-ABL1 transcript level below or equal to 0.1% in the international scale). In contrast, the rs460089-GG represented a risk factor for imatinib failure, which was significantly higher in rs460089-GG_rs2631365-TC carriers. Conclusions This exploratory study depicted potentially important genetic markers predicting outcome of imatinib treatment, which may be helpful for tailoring therapy in clinical practice. Electronic supplementary material The online version of this article (doi:10.1186/s13046-017-0523-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Monika Jaruskova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic.,Institute of Clinical and Experimental Hematology, 1st Medicine Faculty, Charles University, Prague, Czech Republic
| | - Nikola Curik
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic.,Institute of Pathophysiology, 1st Medicine Faculty, Charles University, Prague, Czech Republic
| | - Rajna Hercog
- European Molecular Biology Laboratory, Genomics Core Facility, Heidelberg, Germany
| | - Vaclava Polivkova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic.,Faculty of Science, Charles University, Prague, Czech Republic
| | - Eliska Motlova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic
| | - Vladimir Benes
- European Molecular Biology Laboratory, Genomics Core Facility, Heidelberg, Germany
| | - Hana Klamova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic.,Institute of Clinical and Experimental Hematology, 1st Medicine Faculty, Charles University, Prague, Czech Republic.,CELL, the Czech Leukemia Study Group for Life, Brno, Czech Republic
| | - Pavla Pecherkova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic
| | - Petra Belohlavkova
- CELL, the Czech Leukemia Study Group for Life, Brno, Czech Republic.,4th Department of Internal Medicine Hematology, Charles University Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Filip Vrbacky
- 4th Department of Internal Medicine Hematology, Charles University Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic
| | - Katerina Machova Polakova
- Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic. .,Institute of Clinical and Experimental Hematology, 1st Medicine Faculty, Charles University, Prague, Czech Republic. .,CELL, the Czech Leukemia Study Group for Life, Brno, Czech Republic.
| |
Collapse
|
11
|
Plesingerova H, Librova Z, Plevova K, Libra A, Tichy B, Skuhrova Francova H, Vrbacky F, Smolej L, Mayer J, Bryja V, Doubek M, Pospisilova S. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. Leuk Lymphoma 2016; 58:70-79. [PMID: 27185377 DOI: 10.1080/10428194.2016.1180690] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Patients with unmutated IGHV (U-CLL) usually progress rapidly, whereas patients with mutated IGHV (M-CLL) have a more indolent disease. The expression of several genes correlates closely with the IGHV mutational status and could be used to assess prognosis in CLL. We analyzed the prognostic relevance of COBLL1, LPL, and ZAP70 gene expression, which correlated with IGHV mutational status (p < 0.0001), in 117 CLL patients and established a prognostic parameter dividing the tested cohort according to the disease aggressiveness. Our prognostic parameter was validated on an independent cohort of 161 CLL patients and achieved a high accuracy (94%). Patients divided according to the prognostic parameter differ in overall survival and time to first treatment (p < 0.0001, HR = 2.300/5.970, 95% CI: 1.587-3.450/4.621-15.86). Our approach provides a reliable alternative method to prognosis assessment via IGHV mutational status analysis.
Collapse
Affiliation(s)
- Hana Plesingerova
- a Center of Molecular Medicine, Central European Institute of Technology, Masaryk University , Brno , Czech Republic.,b Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine , Masaryk University and University Hospital Brno , Czech Republic
| | - Zuzana Librova
- c GENERI BIOTECH s.r.o , Hradec Kralove , Czech Republic
| | - Karla Plevova
- a Center of Molecular Medicine, Central European Institute of Technology, Masaryk University , Brno , Czech Republic.,b Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine , Masaryk University and University Hospital Brno , Czech Republic
| | - Antonin Libra
- c GENERI BIOTECH s.r.o , Hradec Kralove , Czech Republic
| | - Boris Tichy
- a Center of Molecular Medicine, Central European Institute of Technology, Masaryk University , Brno , Czech Republic
| | - Hana Skuhrova Francova
- b Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine , Masaryk University and University Hospital Brno , Czech Republic
| | - Filip Vrbacky
- d 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove , University Hospital Hradec Kralove and Charles University , Hradec Kralove , Czech Republic
| | - Lukas Smolej
- d 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove , University Hospital Hradec Kralove and Charles University , Hradec Kralove , Czech Republic
| | - Jiri Mayer
- a Center of Molecular Medicine, Central European Institute of Technology, Masaryk University , Brno , Czech Republic.,b Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine , Masaryk University and University Hospital Brno , Czech Republic
| | - Vitezslav Bryja
- e Department of Cytokinetics, Institute of Biophysics , Academy of Sciences of the Czech Republic , Brno , Czech Republic.,f Institute of Experimental Biology, Faculty of Science , Masaryk University , Brno , Czech Republic
| | - Michael Doubek
- a Center of Molecular Medicine, Central European Institute of Technology, Masaryk University , Brno , Czech Republic.,b Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine , Masaryk University and University Hospital Brno , Czech Republic
| | - Sarka Pospisilova
- a Center of Molecular Medicine, Central European Institute of Technology, Masaryk University , Brno , Czech Republic.,b Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine , Masaryk University and University Hospital Brno , Czech Republic
| |
Collapse
|
12
|
Kacerovsky M, Vrbacky F, Kutova R, Pliskova L, Andrys C, Musilova I, Nekvindova J. 13: Cervical microbiota in women with preterm pre labor rupture of membranes. Am J Obstet Gynecol 2015. [DOI: 10.1016/j.ajog.2015.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Vrbacky F, Nekvindova J, Rezacova V, Simkovic M, Motyckova M, Belada D, Painuly U, Jiruchova Z, Maly J, Krejsek J, Zak P, Cervinka M, Smolej L. Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. Neoplasma 2015; 61:585-92. [PMID: 25030442 DOI: 10.4149/neo_2014_071] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Elevated levels of circulating angiogenic cytokines and increased expression of genes encoding angiogenic factors have been reported in recent years in patients with chronic lymphocytic leukemia (CLL) but data regarding prognostic and predictive significance are still limited. Therefore, in the present study based upon our prior pilot results, we measured mRNA expressions of angiopoietin-2 (Ang-2), fibroblast growth factor-2 (FGF-2) and endoglin (CD105) by reverse transcription quantitative PCR in purified CD19+ cells from 70 untreated CLL patients (median age, 63 years; males, 64%; Rai III/IV stages, 29 %; unmutated IgVH genes, 60 %) and evaluated their possible association with established prognostic factors and clinical course of the disease. Higher expression of Ang-2 was significantly associated with unmutated IgVH genes (n = 55, p = 0.003). Higher CD105 expression was significantly associated with unmutated IgVH genes (n = 55, p < 0.001), high CD38 expression (n = 66, p = 0.022), high ZAP-70 expression (n = 66, p = 0.010), Rai stage I-IV (n = 70, p < 0.001), progressive clinical course of CLL (n = 70, p = 0.001) and shorter time to treatment (n = 70; p < 0.001). Expression of FGF-2 was not significantly associated with any of the prognostic markers. These results indicate that elevated expression of Ang-2 and in particular CD105 by CLL cells is associated with unfavorable prognostic features and clinical outcome; thus, both cytokines appear to play an important role in biology and progression of CLL and warrant further investigation.
Collapse
|
14
|
Kacerovsky M, Vrbacky F, Kutova R, Pliskova L, Andrys C, Musilova I, Menon R, Lamont R, Nekvindova J. Cervical microbiota in women with preterm prelabor rupture of membranes. PLoS One 2015; 10:e0126884. [PMID: 25993616 PMCID: PMC4439143 DOI: 10.1371/journal.pone.0126884] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2014] [Accepted: 04/08/2015] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVE To analyze the cervical microbiota in women with preterm prelabor rupture of membranes (PPROM) by pyrosequencing and to document associations between cervical microbiota, cervical inflammatory response, microbial invasion of the amniotic cavity (MIAC), histological chorioamnionitis, and intraamniotic infection (IAI). STUDY DESIGN Sixty-one women with singleton pregnancies complicated by PPROM were included in the study. Specimens of cervical and amniotic fluid were collected on admission. The cervical microbiota was assessed by 16S rRNA gene sequencing by pyrosequencing. Interleukin (IL)-6 concentration in the cervical fluid and amniotic fluid was measured by ELISA and lateral flow immunoassay, respectively. RESULTS Four bacterial community state types [CST I (Lactobacillus crispatus dominated), CST III (Lactobacillus iners dominated), CST IV-A (non-Lactobacillus bacteria dominated), and CST IV-B (Gardnerella vaginalis and Sneathia sanguinegens dominated)] were observed in the cervical microbiota of women with PPROM. Cervical fluid IL-6 concentrations differed between CSTs (CST I = 145 pg/mL, CST III = 166 pg/mL, CST IV-A = 420 pg/mL, and CST IV-B = 322 pg/mL; p = 0.004). There were also differences in the rates of MIAC, of both MIAC and histological chorioamnionitis, and of IAI among CSTs. No difference in the rate of histological chorioamnionitis was found among CSTs. CONCLUSIONS The cervical microbiota in PPROM women in this study was characterized by four CSTs. The presence of non-Lactobacillus CSTs was associated with a strong cervical inflammatory response and higher rates of MIAC, both MIAC and histological chorioamnionitis, and IAI representing a PPROM subtype with pronounced inflammation. CST I represents the dominant type of PPROM with a low rate of MIAC, IAI, and the combination of MIAC and histological chorioamnionitis.
Collapse
Affiliation(s)
- Marian Kacerovsky
- Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- Department of Obstetrics and Gynecology, Charles University in Prague, Faculty of Medicine Hradec Kralove, Hradec Kralove, Czech Republic
- * E-mail:
| | - Filip Vrbacky
- 4 Department of Medicine, Hematology, University Hospital Hradec Kralove and Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic
| | - Radka Kutova
- Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Lenka Pliskova
- Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Ctirad Andrys
- Department of Clinical Immunology and Allergology, University Hospital Hradec Kralove, Charles University in Prague, Hradec Kralove, Czech Republic
| | - Ivana Musilova
- Department of Obstetrics and Gynecology, Charles University in Prague, Faculty of Medicine Hradec Kralove, Hradec Kralove, Czech Republic
| | - Ramkumar Menon
- Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine & Perinatal Research, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America
| | - Ronald Lamont
- Department of Obstetrics and Gynecology, University of Southern Denmark, Odense University Hospital, Odense, Denmark
| | - Jana Nekvindova
- Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| |
Collapse
|
15
|
Vrbacky F, Smolej L, Vroblova V, Pekova S, Hrudkova M, Cervinka M, Pecka M, Krejsek J, Maly J. Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features. Hematology 2013; 15:210-4. [DOI: 10.1179/102453309x12583347113898] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Affiliation(s)
- F. Vrbacky
- 2nd Department of Internal MedicineDepartment of Clinical Hematology, Faculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic
| | - L. Smolej
- 2nd Department of Internal MedicineDepartment of Clinical Hematology, Faculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic
| | - V. Vroblova
- Institute of Clinical Immunology and AllergologyFaculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic
| | - S. Pekova
- Laboratory for Molecular DiagnosticsChambon Inc., Prague, Czech Republic
| | - M. Hrudkova
- 2nd Department of Internal MedicineDepartment of Clinical Hematology, Faculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic
| | - M. Cervinka
- Department of Medical Biology and GeneticsFaculty of Medicine, Charles University, Hradec Kralove, Czech Republic
| | - M. Pecka
- 2nd Department of Internal MedicineDepartment of Clinical Hematology, Faculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic
| | - J. Krejsek
- Institute of Clinical Immunology and AllergologyFaculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic
| | - J. Maly
- 2nd Department of Internal MedicineDepartment of Clinical Hematology, Faculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic
| |
Collapse
|
16
|
Kostal M, Dulicek P, Maly J, Krajickova D, Vrbacky F, Beranek M. P.2 Cerebral venous thrombosis risk factors. Thromb Res 2011. [DOI: 10.1016/s0049-3848(11)70057-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
17
|
Vroblova V, Vrbacky F, Hrudkova M, Jankovicova K, Schmitzova D, Maly J, Krejsek J, Smolej L. Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia. Eur J Haematol 2010; 84:513-7. [DOI: 10.1111/j.1600-0609.2010.01425.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|